J Cancer Prev.
2021 Dec;26(4):309-317. 10.15430/JCP.2021.26.4.309.
Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report
- Mohammed A
1 - Dashwood RH2
- Dickinson S3
- Disis ML4
- Jaffee EM5
- Johnson 6 BD6
- Khleif SN7
- Pollak MN8,9
- Schlom J10
- Shoemaker RH1
- Stanton SE11
- Wondrak GT12
- You M13
- Zhu H14
- Miller MS1
- Affiliations
-
- 1Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA
- 2Center for Epigenetics & Disease Prevention, Texas A&M Health, College of Medicine, Houston, TX, USA
- 3UA Cancer Center, University of Arizona, Tucson, AZ, USA
- 4UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, WA, USA
- 5Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 6Department of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI, USA
- 7The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
- 8Lady Davis Institute for Medical Research, Jewish General Hospital, Canada
- 9Departments of Medicine and Oncology, McGill University, Montreal, QC, Canada
- 10Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD, USA
- 11Earle A. Chiles Research Institute, Portland, OR, USA
- 12Department of Pharmacology and Toxicology, College of Pharmacy and UA Cancer Center, University of Arizona, Tucson, AZ, USA
- 13Center for Cancer Prevention, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, TX, USA
- 14University of Texas Southwestern Medical Center, Dallas, TX, USA
- KMID: 2524126
- DOI: http://doi.org/10.15430/JCP.2021.26.4.309
Abstract
- The National Cancer Institute (NCI) Division of Cancer Prevention (DCP) convened the “Translational Advances in Cancer Prevention Agent Development (TACPAD) Workshop on Immunomodulatory Agents” as a virtual 2-day workshop on September 13 to 14, 2021. The main goals of this workshop were to foster the exchange of ideas and potentially new collaborative interactions among leading cancer immunoprevention researchers from basic and clinical research and highlight new and emerging trends in immunoprevention. The workshop included an overview of the mechanistic classes of immunomodulatory agents and three sessions covering the gamut from preclinical to clinical studies. The workshop convened individuals working in immunology and cancer prevention to discuss trends in discovery and development of immunomodulatory agents individually and in combination with other chemopreventive agents or vaccines.
